Phage therapy: Combating infections with potential for evolving from merely a treatment for complications to targeting diseases

Frontiers in Microbiology

Volumn 7, Issue SEP, 2016, Pages

  Górski, Andrzej ^a,b   Miedzybrodzki, Ryszard ^a,b   Weber Dabrowska, Beata ^a   Fortuna, Wojciech ^a   Letkiewicz, Sławomir ^a,c   Rogóz, Paweł ^a   Jończyk Matysiak, Ewa ^a   Dabrowska, Krystyna ^a   Majewska, Joanna ^a   Borysowski, Jan ^b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c KATOWICE SCHOOL OF ECONOMICS   (Poland)

Author keywords

Anti phage antibodies; Antibiotic resistance; Bacteriophage; Compassionate use; Inflammation; Phage therapy; Reactive oxygen species

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; TUMOR NECROSIS FACTOR;

ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; BONE MARROW TRANSPLANTATION; DEGRANULATION; DIABETIC FOOT; GREENHOUSE EFFECT; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENCE; IMMUNOMODULATION; INFECTION; INFLAMMATION; PATIENT CARE; REVIEW; STREPTOCOCCUS;

EID: 85053361401     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2016.01515     Document Type: Review

References (73)

1. Bedell, E. (2010). Global Access to Medicinal Products: Compassionate Use Procedures. Available at: www.raps.org
2. Benson, K., and Hartz, A. J. (2000). A comparison of observational studies and randomized, controlled trials. N. Engl. J. Med. 342, 1878-1886. doi: 10.1056/NEJM200006223422506
3. Blaser, M. J. (2014). The microbiome revolution. J. Clin. Invest. 124, 4162-4165. doi: 10.1172/JCI78366
4. Borysowski, J., and Górski, A. (2008). Is phage therapy acceptable in the immunocompromised host? Int. J. Infect Dis. 12, 466-471. doi: 10.1016/j.ijid.2008.01.006
5. Borysowski, J., Wierzbicki, P., Klosowska, D., Korczak-Kowalska, G., Weber-Dabrowska, B., and Górski, A. (2010). The effects of T4 and A3/R phage preparations on whole-blood monocyte and neutrophil respiratory burts. Viral Immunol. 2010, 541-544. doi: 10.1089/vim.2010.0001
6. Brown, T. L., Petrovski, S., Dyson, Z. A., Seviour, R., and Tucci, J. (2016). The formulation of bacteriophage in a semi solid preparation for control of propionibacterium acnes growth. PLoS ONE 11:e0151184. doi: 10.1371/journal.pone.0151184
7. Brussow, H. (2016). Targeting the gut to protect the bladder: oral phage therapy approaches against urinary Escherichia coli infections? Environ. Microbiol. 18, 2084-2088. doi: 10.1111/1462-2920.13310
8. Bruttin, A., and Brüssow, H. (2005). Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob. Agents Chemother. 49, 2874-2878. doi: 10.1128/AAC.49.7.2874-2878.2005
9. Califf, R. M., and Ostroff, S. (2015). FDA as a catalyst for translation. Sci. Transl. Med. 7:296ed9. doi: 10.1126/scitranslmed.aab2404
10. Capparelli, R., Nocerino, N., Lanzetta, R., Silipo, A., Amoresano, A., Giangrande, C., et al. (2010). Bacteriophage-resistant Staphylococcus aureus mutant confers broad immunity against staphylococcal infection in mice. PLoS ONE 5:e11720. doi: 10.1371/journal.pone.0011720
11. Chan, B. K., Abedon, S. T., and Loc-Carrillo, C. (2013). Phage cocktails and the future of phage therapy. Future Microbiol. 8, 769-783. doi: 10.2217/fmb.13.47
12. Chanishvili, N. (2016). Bacteriophages as therapeutic and prophylactic means: summary of the Soviet and Post Soviet experiences. Curr. Drug Deliv. 13, 309-323. doi: 10.2174/156720181303160520193946
13. Chanishvili, N., Chanishvili, T., Tediashvili, M., Goderdzishvili, M., Gogiashvili, D., Malkhazova, Y., et al. (2009). A Literature Review of the Practical Application of Bacteriophage Research. Tbilisi: Eliava Institute of Bacteriophage, Microbiology and Virology.
14. Concato, J., Shah, N., and Horwitz, R. I. (2000). Randomized, controlled trials, observational studies, and the hierarchy of research designs. N. Engl. J. Med. 342, 1887-1892. doi: 10.1056/NEJM200006223422507
15. Czaplewski, L., Bax, R., Clokie, M., Dawson, M., Fairhead, H., Fischetti, V. A., et al. (2016). Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect. Dis. 16, 239-251. doi: 10.1016/S1473-3099(15)00466-1
16. Dabrowska, K., Miernikiewicz, P., Piotrowicz, A., Hodyra, K., Owczarek, B., Lecion, D., et al. (2014). Immunogenicity studies of proteins forming the T4 phage head surface. J. Virol. 88, 12551-12557. doi: 10.1128/JVI.02043-14
17. Debarbieux, L., Pirnay, J. P., Verbeken, G., DeVos, D., Merabishvili, M., Huys, I., et al. (2016). A bacteriophage journey at the European Medicines Agency. FEMS Microbiol. Lett. 363:fnv225, doi: 10.1093/femsle/fnv225
18. Expert round table on acceptance and re-implementation of bacteriophage therapy (2016). Silk route to the acceptance and re-implementation of bacteriophage therapy. Biotechnol J. 11, 595-600. doi: 10.1002/biot.201600023
19. Food and Drug Administration (2013). Paving the Way for Personalized Medicine: FDA'S Role in a New Era of Medicinal Product Development. Washington, DC: Food and Drug Administration.
20. Galtier, M., de Sordi, L., Maura, D., Arachchi, H., Volant, S., Dilles, M. A., et al. (2016). Bacteriophages to reduce gut carriage of antibiotics resistant uropathogens with low impact on microbiota components. Environ. Microbiol. 18, 2237-2245. doi: 10.1111/1462-2920.13284
21. Gill, J. and Young, R.F. (2011). "Therapeutic applications of phage biology: history, practice and recommendations, " in Emerging Trends in Antibacterial Discovery, Answering the Call to Arms, eds A. A. Miller and P. F Miller (Norfolk: Caister Academic Press), 367-407.
22. Górski, A., Dabrowska, K., Hodyra-Stefaniak, K., Borysowski, J., Miedzybrodzki, R., and Weber-Dabrowska, B. (2015). Phages targeting infected tissues: novel approach to phage therapy. Future Microbiol. 10, 199-204. doi: 10.2217/fmb.14.126
23. Górski, A., Dabrowska, K., Switala-Jelen, K., Nowaczyk, M., Weber-Dabrowska, B., Boratynski, J., et al. (2003). New insights into the possible role of bacteriophages in host defense and disease. Med. Immunol. 2:2. doi: 10.1186/1476-9433-2-2
24. Górski, A., Kniotek, M., Perkowska-Ptasinska, A., Mróz, A., Przerwa, A., Gorczyca, W., et al. (2006a). Bacteriophages and transplantation tolerance. Transplant. Proc. 38, 331-333. doi: 10.1016/j.transproceed.2005.12.073
25. Górski, A., Miedzybrodzki, R., Borysowski, J., Dabrowska, K., Wierzbicki, P., Ohams, M., et al. (2012). Phage as a modulator of immune response: practical implications for phage therapy. Adv. Virus Res. 83, 41-71. doi: 10.1016/B978-0-12-394438-2.00002-5
26. Górski, A., Wazna, E., Weber-Dabrowska, B., Switala-Jelen, K., and Miedzybrodzki, R. (2006b). Bacteriophage translocation. FEMS Immunol. Med. Microbiol. 46, 313-316. doi: 10.1111/j.1574-695X.2006.00044.x
27. Górski, A., and Weber-Dabrowska, B. (2005). The potential role of endogenous bacteriophages in controlling invading pathogens. Cell Mol. Life Sci. 62, 511-519. doi: 10.1007/s00018-004-4403-6
28. Henein, A. (2013). What are limitations on the wider therapeutic use of phage therapy? Bacteriophage 3:e24872. doi: 10.4161/bact.24872
29. Hodyra-Stefaniak, K., Miernikiewicz, P., Drapala, J., Drab, M., Jonczyk-Matysiak, E., Lecion, D., et al. (2015). Mammalian host-versus-phage immune response determines phage fate in vivo. Sci. Rep. J. 5:14802. doi: 10.1038/srep14802
30. Jerne, N. K., and Avegno, P. (1956). The development of the phage-inactivating properties of serum during the course of specific immunization of an animal: reversible and irreversible inactivation. J. Immunol. 76, 200-208.
31. Jiang, J., Abu-Shilbayeh, L., and Rao, V. B. (1997). Display of a PorA peptide from Neisseria meningitidis on the bacteriophage T4 capsid surface. Infect. Immun. 65, 4770-4777.
32. Jonczyk-Matysiak, E., Lusiak-Szelachowska, M., Klak, M., Bubak, B., Miedzybrodzki, R., Weber-Dabrowska, B., et al. (2015). The effect of bacteriophage preparations on intracellular killing of bacteria by phagocytes. J. Immun. Res. 2015:482863. doi: 10.1155/2015/482863
33. Kau, A. L., Ahern, P. P., Griffin, N. W., Goodman, A. L., and Gordon, J. I. (2011). Human nutrition, the gut microbiome and the immune system. Nature 474, 327-336. doi: 10.1038/nature10213
34. Kelsey, R. (2016). Stones: gut microbiome is unique in kidney stone disease. Nat. Rev. Urol. 13:368. doi: 10.1038/nurol.2016.93
35. Knoepfler, P. (2016). When patients reach out, scientists should reach back carefully. Nat. Med. 22, 230. doi: 10.1038/nm0316-230
36. Kurzepa, A. (2011). The Influence of Bacteriophage Preparations on Human Phagocyte Migration In vitro. Doctoral thesis, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy Polish Academy of Sciences, Wroclaw.
37. Kutateladze, M., and Adamia, R. (2010). Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 12, 591-595. doi: 10.1016/j.tibtech.2010.08.001
38. Kutter, E. M., Kuhl, S. J., and Abedon, S. T. (2015). Re-establishing a place for phage therapy in western medicine. Future Microbiol. 10, 685-688. doi: 10.2217/fmb.15.28
39. Leon, M., and Bastias, R. (2015). Virulence reduction in bacteriophage resistant bacteria. Front. Microbiol. 6:343. doi: 10.3389/f/micb.2015.00343
40. Leszczynski, P., Weber-Dabrowska, B., Kohutnicka, M., Luczak, M., Górecki, A., and Górski, A. (2006). Successful eradication of methicillin-resistant Staphylococcus aureus (MRSA) intestinal carrier status in a healthcare worker-case report. Folia Microbiol (Praha.) 51, 236-238. doi: 10.1007/BF02932128
41. Letkiewicz, S. (2015). Phage Therapy of Antibiotics-Resistant Bacterial Infections as a Therapeutic Experiment: Ethical Aspects. Warsaw: Warsaw Medical University.
42. Lusiak-Szelachowska, M., Zaczek, M., Weber-Dabrowska, B., Klak, M., Miedzybrodzki, R., Fortuna, W., et al. (2016). "Antiphage activity of sera from patients receiving staphylococcal phage preparations, " in Microbes in the Spotlight: Recent Progress in the Understanding of Beneficial and Harmful Microorganisms, ed. A. Méndez-Vilas (Boca Raton: BrownWalker Press), 245-249.
43. Lusiak-Szelachowska, M., Zaczek, M., Weber-Dabrowska, B., Miedzybrodzki, R., Klak, M., Fortuna, W., et al. (2014). Phage neutralization by sera of patients receiving phage therapy. Viral Immunol. 27, 295-304. doi: 10.1089/vim.2013.0128
44. Ly-Chatain, M. H. (2014). The factors affecting effectiveness of treatment in phages therapy. Front. Microbiol. 5:51. doi: 10.3389/fmicb.2014.00051
45. Majewska, J., Beta, W., Lecion, D., Hodyra-Stefaniak, K., Klopot, A., Kazmierczak, Z., et al. (2015). Oral application of T4 phage induces weak antibody production in the gut and in the blood. Viruses 7, 4783-4799. doi: 10.3390/v7082845
46. McGann, P., Snesrud, E., Maybank, R., Correy, B., Ong, A. C., Clifford, R., et al. (2016). Escherichia coli harboring mcr-1 and blaCTX-M on a novel IncF plasmid: first report of mcr-1 in the USA. Antimicrob. Agents Chemother. 20, 4420-4421. doi: 10.1128/AAC.01103-16
47. Miedzybrodzki, R., Borysowski, J., Weber-Dabrowska, B., Fortuna, W., Letkiewicz, S., Szufnarowski, K., et al. (2012). Clinical aspects of phage therapy. Adv. Virus Res. 83, 73-121. doi: 10.1016/B978-0-12-394438-2.00003-7
48. Miedzybrodzki, R., Fortuna, W., Weber-Dabrowska, B., and Górski, A. (2009). A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clin. Exp. Med. 9, 303-312. doi: 10.1007/s10238-009-0044-2
49. Miedzybrodzki, R., Switala-Jelen, K., Fortuna, W., Weber-Dabrowska, B., Przerwa, A., Lusiak-Szelachowska, M., et al. (2008). Bacteriophage preparation inhibition of reactive oxygen species generation by endotoxin-stimulated polymorphonuclear leukocytes. Virus Res. 131, 233-242. doi: 10.1016/j.virusres.2007.09.013
50. Miernikiewicz, P., Dabrowska, K., Piotrowicz, A., Owczarek, B., Wojas-Turek, J., Kicielinska, J., et al. (2013). T4 phage and its head surface proteins do not stimulate inflammatory mediator production. PLoS ONE 8:e71036. doi: 10.1371/journal.pone.0071036
51. Miernikiewicz, P., Klopot, A., Soluch, R., Szkuta, P., Keska, W., Hodyra-Stefaniak, K., et al. (2016). T4 phage tail adhesion Gp12 counteracts LPS-induced inflammation in vivo. Front. Microbiol. 7:1112. doi: 10.3389/fmicb.2016.01112
52. O'Neill, J. (ed.). (2016). Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. The Review on Antimicrobial Resistance. Available at: http://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf
53. Penner, J. C., Ferreira, J. A., Secor, P. R., Sweere, J. M., Birukova, M., Joubert, L. M., et al. (2016). Pf4 bacteriophage produced by Pseudomonas aeruginosa inhibits Aspergillus fumigates metabolism via iron sequestration. Microbiology. doi: 10.1099/mic.0.000344 [Epub ahead of print].
54. Pincus, N. B., Reckhow, J. D., Saleem, D., Jammeh, M. L., Datta, S. K., and Myles, I. A. (2015). Strain specific phage treatment for Staphylococcus aureus infection is influenced by host immunity and site of infection. PLoS ONE 10:e0124280. doi: 10.1371/journal.pone.0124280
55. Pirnay, J. P., Blasdel, B. G., Bretaudeau, L., Buckling, A., Chanishvili, N., Clark, J., et al. (2015). Quality and safety requirements for sustainable phage therapy products. Pharm. Res. 32, 2172-2179. doi: 10.1007/s11095-014-1617-7
56. Przybylski, M., Borysowski, J., Jkaubowska-Zahorska, R., Weber-Dabrowska, B., and Górski, A. (2015). T4 bacteriophage-mediated inhibition of adsorption and replication of human adenowirus in vitro. Future Microbiol. 10, 453-460. doi: 10.2217/fmb.14.147
57. Sarker, S. A., and Brussow, H. (2016). From bench to bed and back again: phage therapy of childhood Escherichia coli diarrhea. Ann. N. Y. Acad. Sci. 1372, 42-52. doi: 10.1111/nyas.13087
58. Sathaliyawala, T., Rao, M., Maclean, D. M., Birx, D. L., Alving, C. R., and Rao, V. B. (2006). Assembly of human immunodeficiency virus (HIV) antigens on bacteriophage T4: a novel in vitro approach to construct multicomponent HIV vaccines. J. Virol. 80, 7688-7698. doi: 10.1128/JVI.00235-06
59. Servick, K. (2016). Beleaguered phage therapy trial presses on. Science 352:1506. doi: 10.1126/science.352.6293.1506
60. Shivachandra, S. B., Li, Q., Peachman, K. K., Matyas, G. R., Leppa, S. H., Alving, C. R., et al. (2007). Multicomponent anthrax toxin display and delivery using bacteriophage T4. Vaccine 25, 1225-1235. doi: 10.1016/j.vaccine.2006.10.010
61. Shivachandra, S. B., Rao, M., Janosi, L., Sathaliyawala, T., Matyas, G. R., Alving, C. R., et al. (2006). In vitro binding of anthrax protective antigen on bacteriophage T4 capsid surface through Hoc-capsid interactions: a strategy for efficient display of large full-length proteins. Virology 345, 190-198. doi: 10.1016/j.virol.2005.10.037
62. Speck, P., and Smithyman, A. (2016). Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiol. Lett. 363:fnv242. doi: 10.1093/femsle/fn242
63. Sulakvelidze, A., Alavidze, Z., and Morris, J. G. Jr. (2001). Bacteriophage therapy. Antimicrob. Agents Chemother. 45, 649-659. doi: 10.1128/AAC.45.3.649-659.2001
64. The Action to Control Cardiovascular Risk in Diabetes Study Group (2008). Effects of intensive glucose lowering in type 2 diabetes. New Engl. J. Med. 358, 2545-559. doi: 10.1056/NEJMoa0802743
65. Torres-Barcelo, C., and Hochberg, M. E. (2016). Evolutionary rationale for phages as complements of antibiotics. Trends Microbiol. 24, 249-256. doi: 10.1016/j.tim.2015.12.011
66. Vandenheuvel, D., Lavigne, R., and Brussow, H. (2015). Bacteriophage therapy: advances in formulation, strategies and human clinical trials. Annu. Rev. Virol. 2, 599-618. doi: 10.1146/annurev-virology-100114-054915
67. Verbeken, G., Huys, I., DeVos, D., De Coninck, A., Roseeuw, D., Kets, E., et al. (2016). Access to bacteriophage therapy: discouraging experiences from the human cell and tissue legal framework. FEMS Microbiol. Lett. 363:fnv241. doi: 10.1093/femsle/fnv241
68. Verbeken, G., Pirnay, J. P., Lavigne, R., Jennes, S., De Vos, D., Casteels, M., et al. (2014). Call for a dedicated European legal framework for bacteriophage therapy. Arch. Immun. Ther. Exp. 62, 117-129. doi: 10.1007/s00005-014-0269-y
69. Walker, M. J., Rogers, W. A., and Entwistle, V. (2014). Ethical justifications for access to unapproved medical interventions: an argument for (limited) patient obligations. Am. J. Bioeth. 14, 3-15. doi: 10.1080/15265161.2014.957416
70. Weber-Dabrowska, B., Mulczyk, M., and Górski, A. (2003). Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man. Transplant. Proc. 35, 1385-1386. doi: 10.1016/S0041-1345(03)00525-6
71. Whitfield, K., Huemer, K. H., Winter, D., Thirstup, S., Libersa, C. H., Barraud, B., et al. (2010). Compassionate Use of Interventions: Results of a European Clinical Research Infrastructures Network (ECRIN) Survey of Ten European Countries. Available at: http://www.trialsjournal.com/content/11/1/104
72. Young, R., and Gill, J. J. (2015). Phage therapy redux-what is to be done? Science 350, 1163-1164. doi: 10.1126/science.aad6791
73. Zimecki, M., Artym, J., Kocieba, M., Weber-Dabrowska, B., Borysowski, J., and Górski, A. (2010). Prophylactic effects of bacteriophages on mice subjected to chemotherapy-induced immunosuppression and bone marrow transplantation upon infection with Staphylococcus aureus. Med. Microbiol. Immunol. 199, 71-79. doi: 10.1007/s00430-009-0135-4